Drugs / HR20013
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06554184 | Sep 2024 → Jul 2025 | chemotherapy-induced toxicity | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT05509634 | Sep 2022 → Jun 2023 | — | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-06-09 | Jiangsu HengRui Medicine Co., Ltd. | Results 2026 ASCO口头报告︱恒瑞创新药磷罗拉匹坦帕洛诺司琼联合地塞米松预防中致吐性化疗引起的恶心呕吐研究结果发布 hengrui.com ↗
研究结果显示 [1] ，磷罗拉匹坦帕洛诺司琼联合地塞米松组延迟期完全缓解（CR）率为79.0%，显著优于对照组（P<0.001），有望成为中致吐性化疗相关恶心呕吐预防的新选择。 |
| 2026-02-05 | Jiangsu HengRui Medicine Co., Ltd. | Regulatory 恒瑞创新药注射用磷罗拉匹坦帕洛诺司琼新适应症上市许可申请获受理 hengrui.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-09 | Jiangsu HengRui Medicine Co., Ltd. | 2026 ASCO口头报告︱恒瑞创新药磷罗拉匹坦帕洛诺司琼联合地塞米松预防中致吐性化疗引起的恶心呕吐研究结果发布 hengrui.com ↗ |
| 2026-02-05 | Jiangsu HengRui Medicine Co., Ltd. | 恒瑞创新药注射用磷罗拉匹坦帕洛诺司琼新适应症上市许可申请获受理 hengrui.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HR20013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06554184 ↗ |
| Modality | Other / unclassified | “novel fixed-dose intravenous antiemetic combination” PMID 39621965 ↗ Dec 2024 |
| Route | Intravenous | “novel fixed-dose intravenous antiemetic combination” PMID 39621965 ↗ Dec 2024 |